Related Experiment Videos
[Clinical studies on cefpodoxime proxetil in the pediatric fields]
1Department of Pediatrics, Aomori Prefectural Central Hospital.
Insights
Cefpodoxime proxetil (CPDX-PR) effectively treated bacterial infections in children, showing a 77.8% efficacy rate with no observed side effects. This oral cephalosporin derivative is a promising option for pediatric infectious diseases.
Area of Science:
- Pediatric Infectious Diseases
- Bacteriology
- Pharmacology
Context:
- Acute bacterial infections in children require effective and safe oral treatment options.
- Cephalosporins are a class of antibiotics widely used for bacterial infections.
- Cefpodoxime proxetil (CPDX-PR) is an oral third-generation cephalosporin derivative.
Purpose:
- To evaluate the clinical efficacy and safety of cefpodoxime proxetil (CPDX-PR) in children with acute bacterial infections.
- To assess the bacteriological response to CPDX-PR treatment.
- To determine the overall effectiveness of CPDX-PR in a pediatric population.
Summary:
- CPDX-PR was administered orally to 18 children diagnosed with various acute bacterial infections, including tonsillitis, bronchitis, pneumonia, staphylococcal scalded skin syndrome, and impetigo.
- Dosages ranged from 7.5 to 18 mg/kg/day, divided into 2 or 3 doses for 5–15 days.
- An overall clinical efficacy rate of 77.8% was observed (3 excellent, 11 good, 4 fair), with good bacteriological responses in 6 of 7 identified pathogen cases. No adverse effects were reported.
Impact:
- CPDX-PR demonstrated significant clinical effectiveness and a favorable safety profile in treating pediatric bacterial infections.
- The study suggests CPDX-PR is a valuable new oral cephalosporin option for pediatric infectious disease management.
- These findings support the use of CPDX-PR as a reliable therapeutic agent in children.
Abstract:
Cefpodoxime proxetil (CPDX-PR, CS-807) was given orally to 18 children with acute bacterial infections including 10 with acute tonsillitis, 3 with acute bronchitis, 1 with pneumonia, 3 with staphylococcal scalded skin syndrome and 1 with infectious impetigo. Daily dosages per kg bodyweight ranging from 7.5 to 18 mg were given in 2 or 3 divided doses per day for 5 to 15 days. Clinical responses were excellent in 3 (16.7%), good in 11 (61.1%), fair in 4 (22.2%) and poor in 0 (0%), with an overall efficacy rate of 77.8%. Good bacteriological responses were obtained in 6 out of the 7 cases from which pathogens were identified. No side effect was observed. The above results suggest that CPDX-PR is a useful new oral cephalosporin derivative for the treatment of bacterial infections in children.